InflaRx (IFRX) Interest Expense - Debt (2020 - 2021)
InflaRx's (IFRX) quarterly Interest Expense - Debt came in at $16078.5 in Q4 2021, up 5.64% year-over-year from $15219.6 in Q4 2020, and up 5.64% quarter-over-quarter from $15219.6 in Q4 2020.
Powered by 
Analysis
InflaRx (IFRX) Interest Expense - Debt (2020 - 2021) Analysis & Trends
InflaRx has disclosed Interest Expense - Debt across 2 years of filings, most recently posting $16078.5 for Q4 2021.
- In Q4 2021, Interest Expense - Debt rose 5.64% year-over-year to $16078.5; the TTM figure through Dec 2021 stood at $16078.5 (up 5.64% YoY), while the FY2021 annual figure was $16078.5, up 5.64% from the prior year.
- Interest Expense - Debt came in at $16078.5 for Q4 2021 at InflaRx, up from $15219.6 in the prior quarter.
- In the past five years, Interest Expense - Debt ranged from a high of $16078.5 in Q4 2021 to a low of $15219.6 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense - Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | - |